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Burkholderia mallei and Burkholderia pseudomallei are Gram-negative bacteria that cause
glanders and melioidosis, respectively. Inhalational infection with either organism can
result in severe and rapidly fatal pneumonia. Inoculation by the oral and cutaneous routes
can also produce infection. Chronic infection may develop after recovery from acute
infection with both agents, and control of infection with antibiotics requires prolonged
treatment. Symptoms for both meliodosis and glanders are non-specific, making diagnosis
difficult. B. pseudomallei can be located in the environment, but in the host, B. mallei
and B. psedomallei are intracellular organisms, and infection results in similar immune
responses to both agents. Effective early innate immune responses are critical to
controlling the early phase of the infection. Innate immune signaling molecules such
as TLR, NOD, MyD88, and pro-inflammatory cytokines such as IFN-γ and TNF-α play
key roles in regulating control of infection. Neutrophils and monocytes are critical cells
in the early infection for both microorganisms. Both monocytes and macrophages are
necessary for limiting dissemination of B. pseudomallei. In contrast, the role of adaptive
immune responses in controlling Burkholderia infection is less well understood. However,
T cell responses are critical for vaccine protection from Burkholderia infection. At present,
effective vaccines for prevention of glanders or meliodosis have not been developed,
although recently development of Burkholderia vaccines has received renewed attention.
This review will summarize current and past approaches to develop B. mallei and
B. pseudomalllei vaccines, with emphasis on immune mechanisms of protection and the
challenges facing the field. At present, immunization with live attenuated bacteria provides
the most effective and durable immunity, and it is important therefore to understand the
immune correlates of protection induced by live attenuated vaccines. Subunit vaccines
have typically provided less robust immunity, but are safer to administer to a wider variety
of people, including immune compromised individuals because they do not reactivate or
cause disease. The challenges facing B. mallei and B. pseudomalllei vaccine development
include identification of broadly protective antigens, design of efficient vaccine delivery
and adjuvant systems, and a better understanding of the correlates of protection from
both acute and chronic infection.
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INTRODUCTION: DISEASES CAUSED BY B. mallei AND
B. pseudomallei INFECTION
Glanders is the clinical disease caused by Burkholderia mallei
infection. Horses, mules, and donkeys are highly susceptible
to this bacterium and these infected animals serve as a nat-
ural reservoir, since the organism is not able to survive in
the environment alone. Equine glanders transmission occurs
though ingestion or direct contact with fomites. These zoonotic
infections occur by contact with infected animals or follow-
ing direct contact with B. mallei bacterial cultures (Dvorak
and Spickler, 2008). The symptoms of glanders depend upon
the route of infection and are often characterized by pneu-
monia, septicemia, and chronic suppurative infections of the
skin (Srinivasan et al., 2001; Anuntagool and Sirisinha, 2002;
Rosenbloom et al., 2002).
B. mallei infection spreads primarily hematogenously, and
studies in hamster infection models have demonstrated lesions
in the liver, spleen and lungs 6 h after intraperitoneal (i.p.)
inoculation (Fritz et al., 1999). The host immune response to
B. mallei depends critically on activation of innate immune
responses (Goodyear et al., 2010, 2012b), whereas there is limited
knowledge regarding adaptive immune responses during glanders
infection.
Melioidosis is caused by infection with Burkholderia pseudo-
mallei and the agent can cause infection in humans and animals
(Cheng and Currie, 2005). The disease can develop following
subcutaneous (s.c.) inoculation or ingestion or inhalation of the
bacterium (Wiersinga and Van Der Poll, 2009). Certain envi-
ronmental conditions can also increase the risk of contracting
melioidosis. For example the rainy season may be associated with
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increased risk of septic and pneumonic forms of melioidosis
(Currie and Jacups, 2003). As is the case with glanders, the route
of B. pseudomallei infection also contributes to the severity of the
disease (Barnes and Ketheesan, 2005).
B. pseudomallei infect a variety of cells, including mononu-
clear phagocytes and some non-phagocytic cells. Once inside
macrophages, the organism can escape endocytic vesicles and live
free within the cytoplasm (Jones et al., 1996). B. mallei and B
pseudomallei use BimA, a protein required for actin-based motil-
ity (Stevens et al., 2005b) and BimA homologuous proteins for
cell-to-cell spread (Stevens et al., 2005a; Allwood et al., 2011)
and the formation of multi-nucleate giant cells (Harley et al.,
1998). In vivo, the bacterium can spread hematogenously to the
liver, spleen or brain, and can also produce sepsis. However, the
events underlying the spread of B. pseudomallei and the apparent
predilection for sites such as the brain remain poorly understood
(White, 2003; Owen et al., 2009). The olfactory sensory nerve is
the main route to melioidosis brain infection (and to some degree
the trigeminal nerve), though the authors could not explain the
mechanism of travel ofB. pseudomallei via the nerves (Owen et al.,
2009).
The development of symptoms of melioidosis is dependent on
several factors, including bacterial strain differences, variations
in the host immune response, and the route of infection (Cheng
and Currie, 2005). Acute infection is associated with severe pneu-
monia or rapid septicemias (Chaowagul et al., 1989). In the
chronic stages of infection, meliodosis can lead to the forma-
tion of abscesses in multiple organs, or can lead to asymptomatic
infection, which can apparently be reactivated after many years
(Ngauy et al., 2005). Recent studies by our group suggest that the
site of asymptomatic infectionmay actually be the gastrointestinal
tract (Goodyear et al., 2012a).
Currently both B. pseudomallei and B. mallei are considered
as potential bioweapons and they are classified by the Centers for
Disease Control as category B select agents (Dance, 2002; Warawa
and Woods, 2002). The use of B. mallei and B. pseudomallei as
bioweapon stems primarily from the fact that clinical disease can
develop following inhalational exposure to even very low infec-
tive doses of the organisms. In addition, B. pseudomallei is also
endemic in the soil and water of certain regions of the world,
adding to the ease with which bacterial strains can be isolated and
propagated (Currie and Jacups, 2003; Peacock, 2006; Gilad et al.,
2007; Ko et al., 2007). The B. pseudomallei organism can also be
easily manipulated genetically (Mack and Titball, 1996). Effective
treatment of melioidosis is limited by inherent bacterial resistance
to several different classes of antibiotics and treatment of acute
illness is typically associated with high morbidity and mortality
rates (Warawa andWoods, 2002). For all the reasons noted above,
development of effective B. mallei and B. pseudomallei vaccines
are a priority in the emerging infectious disease field.
HOST IMMUNE RESPONSE TO Burkholderia INFECTION
Clinical and experimental studies indicate that Burkholderia
infection rapidly activates the innate immune system. Depending
on the dose and route of infection, the organism can be rapidly
eliminated by this early innate immune response, primarily
through the actions of monocytes and natural killer (NK) cells.
Macrophages play a critical role in the early phase of infec-
tion by controlling organism replication (Breitbach et al., 2006).
However, if the initial infection is not controlled and chronic
infection is established, CD4+ T cells become more important
for long-term control of infection (Haque et al., 2006b). By deter-
mining what is required for a successful immune response against
acute or chronic Burkholderia infection, it may also be possi-
ble to elucidate what is required for successful vaccine-induced
protective immunity.
INNATE IMMUNE RESPONSES TO Burkholderia INFECTION
A fully functional innate immune system is critical to the effi-
cient, early control of Burkholderia infection. The innate immune
response to Burkholderia has been investigated in much greater
detail than the adaptive immune response. Several key cell types
are activated following Burkholderia infection, along with their
cell surface signaling molecules, including Toll-like receptors
(TLRs), NOD-like receptors (NLRs) and caspases. Key cytokines
includingMCP-1, INF-γ, and TNF-α also are required for protec-
tive immunity to Burkholderia infection.
Role of TLR signaling in Burkholderia infection
Cell surface expression of TLR1, TLR2, and TLR4 is upregu-
lated on monocytes and neutrophils from patients infected with
B. pseudomallei (Wiersinga et al., 2007a). Unlike the case with
many Gram-negative pathogens, the lipopolysaccharide (LPS)
from B. pseudomallei appears to activate macrophages only
through TLR2 and not via TLR4 (Wiersinga et al., 2007b). Thus,
in B. pseudomallei infection, TLR2 can be stimulated directly,
whereas activation of TLR4 requires the coreceptors CD14 and
MD2 (Hii et al., 2008). Mice lacking the TLR2 receptor are
actually protected from B. pseudomallei infection, whereas TLR4
defective mice do not exhibit increased susceptibility to either
B. mallei or B. pseudomallei infection (Wiersinga et al., 2007b;
Goodyear et al., 2012b). Macrophage activation by B. pseu-
domallei results in production of pro-inflammatory cytokines,
including TNF-α, IL-1β, and IL-6 (West et al., 2008). Host sus-
ceptibility to melioidosis is modulated by TLR polymorphisms,
but the mechanisms of this effect are not well understood. For
example: TLR4 polymorphisms are associated with increased risk
of melioidosis and TLR6-1-10 region single nucleotide poly-
morphisms in diabetes patients are associated with differential
susceptibility to melioidosis compared with other illnesses (West
et al., 2012).
NLRs and Burkholderia infection
The NLRs NOD1 or NOD2 regulate IL-18 production following
B. pseudomallei infection (Hii et al., 2008). Production of IL-18 in
response to inflammasome signaling was shown to be protective
against B. pseudomallei infection (Wiersinga et al., 2007c). Mice
deficient in inflammasome components including ASC, caspase-
1, NLRC4, and NLRP3 were more susceptible to B. pseudomallei
infection than wild type animals (Ceballos-Olvera et al., 2011).
MyD88 signaling
MyD88 signaling plays a key role in the protection against infec-
tion with both B. pseudomallei and B. mallei. For example,
Frontiers in Cellular and Infection Microbiology www.frontiersin.org March 2013 | Volume 3 | Article 10 | 2
Silva and Dow Burkholderia vaccines
MyD88−/− mice infected with either B. pseudomallei or B. mallei
were much more susceptible to infection than wild type mice
(Wiersinga et al., 2008; Goodyear et al., 2012b). Interestingly, in
MyD88−/− mice infected with B. pseudomallei, there was reduced
early pulmonary neutrophil recruitment and a diminished activa-
tion of neutrophils compared to wild type mice (Wiersinga et al.,
2008). The MyD88-dependent pathway may also contribute to a
detrimental host inflammatory response (Ventura et al., 2009).
MyD88−/− mice infected with B. mallei showed a decreased
inflammatory response (Goodyear et al., 2012b). For example,
numbers of monocytes, myeloid dendritic cells (DC) and neu-
trophils in the lungs of B. mallei infected MyD88−/− mice were
reduced compared to wild type animals. The key defect in the
MyD88−/− mice infected with B. mallei appeared to be a lack of
IFN-γ production, as IFN-γ production was completely absent
in MyD88−/− animals and treatment of MyD88−/− animals with
rIFN-γ partially restored protective immunity (Goodyear et al.,
2012b).
Role of Caspase-1 in Burkholderia infection
B. pseudomallei infection was shown to induce caspase-1 activa-
tion, causing macrophage cell death and triggering the release of
IL-1β and IL-18 (Sun et al., 2005). The caspase-1 pathway was
also shown to regulate IFN-γ production following B. pseudo-
mallei infection. Caspase-1−/− mice were highly susceptible to
B. pseudomallei infection with high bacterial loads and greatly
diminished production of IFN-γ (Breitbach et al., 2009).
Role of MCP-1 in Burkholderia infection
Monocyte chemoattractant protein-1 (MCP-1) was shown
recently to play a critical role in protective immunity to B. mallei
respiratory infection (Goodyear et al., 2010). Both MCP-1−/−
mice and mice lacking the MCP-1 receptor (CCR2−/− mice)
were more susceptible to B. mallei infection, with significantly
higher bacterial burdens in lung, liver and spleen 3 days follow-
ing intranasal challenge compared to wild type animals. Lack
of monocyte and inflammatory DC recruitment to the lungs
appeared to be the primary defect in MCP-1−/− animals, and
in fact these animals actually had significantly greater numbers
of neutrophils in the lungs. In addition, IFN-γ concentrations
were markedly decreased in infected MCP-1−/− and CCR2−/−
mice. Treatment with exogenous rIFN-γ helped restore effective
immunity and increased survival significantly (Goodyear et al.,
2010).
Role of TNF-α
TNF-α is required to control the infection caused by B. pseudoma-
llei in mouse models. For example, TNF-α−/− mice were much
more susceptible to B. pseudomallei infection, with increased
bacterial loads in spleen and liver and high mortality rates of
TNF-α−/−, TNFR1, and TNFR2−/− animals (Barnes et al., 2008).
However, in human melioidosis patients with sepsis, increased
TNF-α production is thought to actually be associated with
higher mortality rates (Suputtamongkol et al., 1992). While
BALB/c and C57Bl/6 mice both readily develop chronic infec-
tion, BALB/c mice are more susceptible to acute infection (Liu
et al., 2002). There are some notable differences in the immune
response to B. pseudomallei between mouse strains. For exam-
ple, TNF-α concentrations were markedly higher in the livers of
BALB/c mice following lethal B. pseudomallei infection, whereas
concentrations were lower in the livers of C57Bl/6 mice (Ulett
et al., 2000). Thus, TNF-α appears to play a dual role in regulation
of both protection and susceptibility to Burkholderia infection. It
would therefore be difficult to predict whether vaccine induction
of TNF-α production would be a desirable biological endpoint.
Role of IFN-γ
Unlike TNF-α, the role of IFN-γ in protection from Burkholderia
infection is unambiguous and IFN-γ is obviously a key protective
cytokine. For example, IFN-γ−/− mice are highly susceptible to
infection with both B. mallei and B. pseudomallei (Santanirand
et al., 1999; Haque et al., 2006b; Koo and Gan, 2006; Rowland
et al., 2006; Easton et al., 2007; Goodyear et al., 2009, 2010).
In addition, mice depleted of IFN-γ with antibodies are also
very susceptible to infection (Santanirand et al., 1999; Breitbach
et al., 2006; Haque et al., 2006b; Whitlock et al., 2008; Wiersinga
et al., 2008). IFN-γ production regulates intracellular killing of
Burkholderia and organ burdens are uniformly higher in IFN-
γ−/− mice compared to wild type animals infected with B. pseu-
domallei. The source of IFN-γ production in vivo has not been
fully elucidated, but our studies have shown high levels of IFN-
γ production by NK cells in the lungs (Goodyear et al., 2009).
In vitro studies have shown that B. pseudomallei infection elic-
its IFN-γ production from NK cells, NKT cells, and conventional
T cells in an IL-12 and IL-18-dependent manner (Haque et al.,
2006b).
Role of IL-12
The presence of both subunits of IL-12 (IL-12p40 and IL-12p35)
was shown to be critical for IFN-γ production in vitro in response
to heat-killed B. mallei (Rowland et al., 2006). In addition, neu-
tralization of IL-12 in vivo resulted in increased susceptibility of
mice to lethal infection (Santanirand et al., 1999). The role of
IL-12 may be primarily to drive NK cells and T cells to IFN-γ
production.
INNATE CELLULAR IMMUNITY TO Burkholderia INFECTION
Role of macrophages
Macrophages play a critical role in early stages of B. pseu-
domallei infection, as deduced from studies in C57BL/6 and
BALB/c mice (Breitbach et al., 2006). Macrophage killing of
Burkholderia is dependent on the presence of IFN-γ derived from
NK cells, CD8+, and TCR-γδ T cells (Rowland et al., 2006).
Though controversial, there is also evidence that iNOS is also
required for macrophage control of B. pseudomallei infection,
though in vitro and in vivo experiments give conflicting results
in this regard (Utaisincharoen et al., 2004; Breitbach et al., 2006,
2011). Macrophage dysfunction in diabetes mellitus is thought
to explain in part the extreme susceptibility of diabetics to lethal
meliodosis infection (Hodgson et al., 2011).
Role of monocytes
Recent studies performed in our laboratory indicate that mono-
cytes play a critical role in the early control of B. mallei infection
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(Goodyear et al., 2010). For example, mice in which monocyte
migration is impaired (CCR2−/− mice) are extremely suscep-
tible to inhaled and parenteral challenge with B. mallei. This
increased susceptibility is associated with significant impairment
in monocyte and DC entry into the lungs following inhala-
tional challenge with B. mallei. In these mice, production of
IL-12 by inflammatory DC is also significantly impaired follow-
ing B. mallei challenge. In another study, depletion of monocytes
using a depleting antibody to Gr-1 also increased susceptibility to
B. pseudomallei infection (Rowland et al., 2010).
Role of neutrophils
Gr-1+ neutrophils are also essential to early control of B. mallei
infection, based on the results of antibody depletion studies
(Rowland et al., 2010). Neutrophil depletion with a cross-reactive
Gr-1 antibody severely exacerbated disease, resulting in an acute
lethal infection associated with a 1000-fold increase in lung bac-
terial loads within 4 days. Neutrophils also play an important
indirect role in the generation of the early cytokine environ-
ment in the lungs (Easton et al., 2007). Neutrophil dysfunction
may also help explain the increased susceptibility of diabetics
to meliodosis, as polymorphonuclear (PMN) cell responses to
B. pseudomallei were impaired due to defects in migration and
apoptosis (Chanchamroen et al., 2009).
Role of natural killer cells
NK cells are estimated to produce up to 80% of IFN-γ in the early
stages of B. pseudomallei infection and IFN-γ is a key cytokine
for control of B. pseudomallei infection (Haque et al., 2006b).
NK cells are also the major source of IFN-γ production in early
B. mallei infection (Rowland et al., 2006; Goodyear et al., 2012b).
Thus, NK cells may help control Burkholderia infection indi-
rectly by activating macrophages via IFN-γ to kill intracellular
Burkholderia.
ADAPTIVE IMMUNE RESPONSE TO Burkholderia
While the role of innate immunity in controlling both B. mallei
and B. pseudomallei infections has been investigated in relative
detail, much less is known about the role of adaptive immune
responses (T cell and B cell responses) in controlling Burkholderia
infection.
Role of T cells
Protection against B. pseudomallei infection appears to depend
on both strong humoral and cell-mediated immunity (Healey
et al., 2005). For example, CD4+ T cells were shown in mouse
infectionmodels to play an important role in resistance to B. pseu-
domallei infection during the later stages of the acute infection
(Haque et al., 2006b). In contrast, the same authors found that
CD8+ T cells were much less important in resistance to melioido-
sis (Haque et al., 2006b). However, in general very little is known
regarding the role of specific T cells subsets in regulating the
tempo or the course of Burkholderia infection.
Role of B cells and antibodies
IgM antibodies were detected only in patients with localized
B. pseudomallei infection. On the other hand, IgG antibodies were
detected in patients during the acute infection. IgG1 and IgG2
antibodies were observed in all patient groups while an IgG3
response was seen only in survivors of septicaemic infection, sug-
gesting that these antibody isotypes may be a good indicator of
active disease (Ho et al., 1997) or a good monitor of therapy (Vasu
et al., 2003). The level of IgA, IgG, and IgM titers increase during
an active infection with glanders, but the titers decreased within
14 months after infection (Waag et al., 2012).
Serum from meliododis patients contains antibodies that tar-
get LPS (Bryan et al., 1994; Ho et al., 1997; Charuchaimontri
et al., 1999; Chenthamarakshan et al., 2001). A monoclonal anti-
body (Mab Ps6F6) specific to B. pseudomallei exopolysaccharide
offered significant protection in a murine sub-acute meliodosis
model. The Mab Ps6F6 provided a moderate and transient reduc-
tion of inflammatory responses in infected mice but was only
partially protection because this antibody was not able to provide
sterilizing protective immunity (Bottex et al., 2005). Antibodies
to Burkholderia Hep_Hag autotransporter (BuHA) proteins were
present in horses with glanders and in human patients with
melioidosis (Tiyawisutsri et al., 2007).
There is also evidence for an important protective role for
B cells and antibodies in Burkholderia infection. For exam-
ple, depletion of B cells significantly decreased survival time of
B. mallei-infected BALB/c mice compared to non-depleted con-
trols (Whitlock et al., 2008). It was speculated that antibody
opsonization increased intracellular killing of B. mallei by increas-
ing uptake by macrophages, but this was not formally demon-
strated. Other studies have proposed that antibodies increase
phagocytosis of Burkholderia (Bryan et al., 1994). Conversely,
however, in a separate study when μMT mice (which lack all B
cells) were infected with B. mallei, the B cell deficient animals
were not found to be more susceptible to infection than wild type
mice (Rowland et al., 2010). It is difficult to fully reconcile these
very different results at present, but the discordant results could
be a consequence of how B cells were depleted, of unanticipated
effects of B cell depletion versus genetic deletion of B cells, or in
the particular challenge models that were used in the studies.
TARGETS FOR VACCINATION AGAINST Burkholderia
Currently, prolonged antibiotic therapy and early diagnosis are
the only options for controlling infections with either B. mallei
or B. pseudomallei. While B. mallei remain uncommon and
largely controlled in the equine population, except in some Asian
and African countries, B. pseudomallei is much more widely
distributed worldwide (Blancou, 1994; Currie et al., 2008). In
fact, recent studies point to an expanded range of B. pseudoma-
llei endemic countries, including Brazil, Central America, and
regions of Asia and India.
While these data do not necessarily suggest that B. pseudoma-
llei is spreading, they do point out that a much greater population
of civilians has some risk of contracting B. pseudomallei infection
from their environment. However, the incidence of meliodosis
does not currently justify vaccination, except in certain regions
such as Thailand and northern Australia where the disease inci-
dence is high enough to warrant consideration of a prophylactic
vaccine. However, there are currently no approved vaccines for
either meliodosis or glanders prevention in humans or animals.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org March 2013 | Volume 3 | Article 10 | 4
Silva and Dow Burkholderia vaccines
Thus, it is believed that efforts to develop a new Burkholderia vac-
cine can be readily justified. In the last portion of this review,
we will discuss the various approaches that have been taken to
produce effective Burkholderia vaccines. One substantial hurdle
that must be overcome by Burkholderia vaccines is to protect
from both acute infection and chronic infection. The latter is a
much more difficult hurdle and few vaccines have demonstrated
a convincing ability to fully protect from the development of the
chronic infection phase of B. pseudomallei infection. Efforts to
produce a Burkholderia vaccine can be broadly classified as sub-
unit vaccines, live attenuated vaccines, and killed bacteria vaccines
delivered with or without adjuvants. Table 1 summarizes several
attempts to provide vaccine-mediated protection against glanders
and melioidosis.
BACTERIAL VIRULENCE FACTORS AS POTENTIAL IMMUNE TARGETS
FOR VACCINATION
The ability to target bacterial virulence factors with vaccines
has the potential to greatly attenuate the pathogenicity of
Burkholderia and thereby suppress replication, allowing the host
immune system to eradicate the organism before infection is well-
established. A number of Burkholderia virulence factors have been
identified and several have been evaluated as vaccine candidates.
Type III and VI secretion systems
B. pseudomallei type III secretion systems (T3SS) plays a role in
early vacuolar escape, cell to cell spread in macrophages, and vir-
ulence (Stevens et al., 2002; Warawa and Woods, 2005; Burtnick
et al., 2008). One component of the T3SS (BipD) has been tested
as a candidate vaccine. Mice vaccinated by the i.p. route had a
slightly prolonged early survival and reduced bacterial burden,
but in general survival times were not prolonged compared to
non-vaccinated mice subjected to the same B. pseudomallei chal-
lenge (Stevens et al., 2004). Other proteins from the T3SS system
(BipB, BipC, or BipD) have also been evaluated as candidate vac-
cines, however, none of these three antigens generated protective
immunity in challenge studies (Druar et al., 2008). In studies in
our laboratory, we noted that intranasal vacctination of mice with
BimA and two other Burkholderia antigens, induced protective
immunity against an inhaled challenge (Whitlock et al., 2010).
The type VI secretion system (T6SS) is an important vir-
ulence factor that is necessary for the intracellular lifestyle of
B. pseudomallei. Studies have shown that the T6SS Hcp1 protein
from B. pseudomallei and B. mallei was recognized by convales-
cent serum from humans with documented meliodosis (Schell
et al., 2007). Moreover, the T6SS proteins Hcp1, Hcp2, Hcp3,
Hcp4, Hcp5, and Hcp6 have all been evaluated individually as
candidate B. pseudomallei vaccines, but each has failed to pro-
vide complete protection in murine challenge models evaluated
to date (Burtnick et al., 2011). However, it remains conceivable
that a multi-valent T6SS vaccine could generate more effective
immunity.
Quorum sensing molecules
Quorum sensing is important to the pathogencity of
Burkholderia. In this process, molecules secreted by bacteria
growing under conditions of crowding or stress help to regulate
metabolism and survival functions of bacteria. LuxL and LuxR
[N-acyl-homoserine lactone (AHL) receptors] are the most
common signaling molecules found in gram negative bacteria
and are also the major quorum sensing molecules involved in
the virulence process of Burkholderia (Whitehead et al., 2001;
Eberl, 2006). A B. pseudomallei LuxL mutant was significantly
attenuated for infection in mice (Ulrich et al., 2004). The
ability of several different B. mallei LuxI mutants to function
as attenuated vaccines was also evaluated, using bmaII, bmaI3,
and bmaR5 mutants, followed by challenge with fully virulent
B. mallei. Only mice vaccinated with the bmaI3 mutant showed
any level of protection, with survival of 3 of the 10 animals, 11
days after challenge (Ulrich et al., 2004).
Surface expressed molecules as vaccine targets
LPS and capsular polysaccharide (CPS) are the main surface-
associated antigens of B. mallei and B. pseudomallei (Perry et al.,
1995; Deshazer et al., 1998; Reckseidler et al., 2001; Atkins et al.,
2002a; Sarkar-Tyson et al., 2007; Tuanyok et al., 2012). B. pseu-
domallei CPS is essential to bacterial virulence and this anti-
gen activates the Th1 immune response (Warawa et al., 2009).
Immunization against either antigen has been shown to pro-
vide partial protection against intranasal challenge with virulent
B. pseudomallei (Trevino et al., 2006; Aucoin et al., 2012). The
combination of both antigens provided better protection, even
when administered in lower doses (Charuchaimontri et al., 1999;
Jones et al., 2002; Nelson et al., 2004; Zhang et al., 2011). However,
the antigen combination did not provide sterilizing immunity
but did significantly decrease the bacterial burden in the spleen
(Aucoin et al., 2012). In another study, vaccination with a mutant
type II O-antigenic polysaccharide (O-PS) molecule also pro-
vided partial protection from infection with B. pseudomallei
infection (Deshazer et al., 1998).
The efficacy of LPS or CPS as vaccines was tested in BALB/c
mice (Nelson et al., 2004; Ngugi et al., 2010). Strong IgM and
IgG3 responses were observed in mice vaccinated with LPS,
whereas higher IgG2b responses were noted in mice immunized
with CPS. After challenge with virulent B. pseudomallei by the i.p.
route, there was partial protection in mice vaccinated with LPS,
with 50% survival by day 35. Partial protection was also observed
in the group vaccinated with CPS. However, whenmice were chal-
lenged by the pulmonary route, there was no protection (Nelson
et al., 2004). Thus, it appears that both LPS and CPS are impor-
tant candidate vaccine antigens. Both antigens appear to provide
at least partial protection from challenge with Burkholderia by
parenteral routes, whereas neither has been particularly effective
for protection from challenge by the inhalational route. In addi-
tion, neither LPS nor CPS vaccines protect from the development
of chronic infection.
The ability of anti-LPS and anti-CPSmonoclonal antibodies to
provide passive protection from challenge with Burkholderia has
also been evaluated. When mice were administered mAbs against
LPS or CPS, there was protection against i.p. challenge with 104
CFU of a virulent strain of B. pseudomallei (NCTC 4845) (Jones
et al., 2002). However, at higher challenge doses, only a mixture
of both mAbs was able to provide significant protection. In addi-
tion, the mAbs did not provide protection from aerosol challenge
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with B. pseudomallei (Nelson et al., 2004). Infusion of an anti-LPS
antibody also protected mice from glanders when administered
immediately prior to lethal challenge with B.mallei (Trevino et al.,
2006).
Flagellin
Flagellin is an important molecule required for motility by
B. pseudomallei (B. mallei does not have a flagellin molecule)
(Deshazer et al., 1997; Wajanarogana et al., 1999; Chua et al.,
2003; Nierman et al., 2004). In one study BALB/c mice were
vaccinated with plasmid DNA encoding the flagellin gene fliC.
Following intravenous challenge, 83% of the vaccinated mice
survived for 7 days. Besides the increased survival rate, the vac-
cinated mice had a higher level of flagellin-specific antibodies and
a higher level of IFN-γ production by splenocytes. It was sug-
gested that the mechanism of protection was provided by the Th1
immune response due to the increased production of IFN-γ and
the higher ratio of the IgG2a/IgG1 antibody response (Chen et al.,
2006). Administration of a mAb directed against flagellin also
provided partial protection (55%) to diabetic rats challenged by
the i.p. route with B. pseudomallei (Brett et al., 1994). It was spec-
ulated that anti-flagellin antibodies may immobilize Burkholderia
and thereby attenuate pathogenicity (Brett et al., 1994; Deshazer
et al., 1997).
Outer membrane proteins
An outer membrane protein was evaluated as a meloidosis vac-
cine (Hara et al., 2009; Su et al., 2010). Immunization in BALB/c
mice with outer membrane protein 85 (Omp85) using Freund’s
complete adjuvant, promoted a strong antibody responses and
provided significant protection against B. pseudomallei D286
challenge with 70% of survival at 15 days post infection. However,
sterilizing immunity was not achieved, as vaccinated mice devel-
oped chronic infection (Su et al., 2010).
Burkholderia pseudomallei PROTEIN SUBUNIT VACCINES
Several different immunogenic proteins of Burkholderia have
been identified as potential candidate vaccine antigens. Protein
subunit vaccines are appealing because vaccine production is sim-
plified and with newer adjuvants many proteins can be rendered
highly immunogenic.
Non-membrane proteins
Three different B. pseudomallei proteins from ATP-binding cas-
sette (ABC) transport systems have been evaluated as potential
vaccine candidates. One is LolC, which is an ABC transporter
protein, first identified as an immunogen (Yakushi et al., 2000;
Harland et al., 2007). The second antigen is PotF, which is a
periplasmic binding protein of the PotFGHI system (Shah and
Swiatlo, 2006) and is a homolog of the Agrobacterium tumefaciens
PotF which is required for attachment and virulence (Matthysse
et al., 1996). A third antigen (OppA), which is an oligopeptide-
binding protein of the Opp system in E. coli (Detmers et al., 2001),
has also been identified as a potential immunogen (Tanabe et al.,
2006; Harland et al., 2007). Immunization with each of these pro-
teins has been shown to stimulate antigen-specific humoral and
cellular immune responses (Harland et al., 2007). Immunization
with recombinant LolC or PotF proteins generated significant
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protection against B. pseudomallei challenge by the i.p. route and
provided greater than 50% protection (Harland et al., 2007). In
contrast, immunization with recombinant OppA protein did not
generate significant protection. Since the LolC is also present in
B. mallei, the authors speculated that LolC protein may also pro-
tect against glanders but this was not tested in the study (Harland
et al., 2007).
In another study, immunogenic antigens were identified from
a genomic screen of B. mallei expressed proteins. Three of these
antigens, including LolC, were found to provide partial protection
against B.mallei andB. pseudomallei following intranasal vaccina-
tion (Whitlock et al., 2010, 2011). Notably, the LolC antigen was
shown to provide cross-protection against both B. pseudomallei
and B. mallei in this intranasal vaccinationmodel (Whitlock et al.,
2010, 2011). Thus, it appears that protein subunit vaccines target-
ing highly immunogenic Burkholderia proteins have the potential
to be used as effective vaccines. However, it is likely that polyva-
lent vaccines combining several antigens may be more effective
than single antigen vaccines.
Burkholderia LIVE ATTENUATEDVACCINES
A number of different live attenuated Burkholderia vaccines have
been developed and evaluated in mouse challenge models. In
general, live attenuated vaccines have been found to provide
superior protective immunity when compared to other poten-
tial Burkholderia vaccines. However, the use of live attenuated
vaccines by parenteral routes of immunization is associated
with more safety and production issues compared with subunit
vaccines.
B. pseudomallei live attenuated vaccines
Several different attenuated strains of Burkholderia have been
evaluated as potential live vaccine strains for protection from
B. pseudomallei. A number of different attenuation strategies have
been investigated to produce these candidate vaccines.
The most extensively investigated live attenuated vaccine to
date has been the 2D2, which is an auxotroph for branched chain
amino acids. It is a mutant strain of B. pseudomallei, which was
produced by mutating the ilvI gene encoding the large subunit of
the acetolactate synthase enzyme (Atkins et al., 2002b). The 2D2
strain of B. pseudomallei was also shown not to persist in vivo
following immunization (Atkins et al., 2002b). When BALB/c
mice were vaccinated with 2D2 by the i.p route, there was sig-
nificant but incomplete protection against i.p. challenge of fully
virulent wild type B. pseudomallei. The incomplete protection was
melioidosis specific since protection against Francisella tularensis,
was not observed (Atkins et al., 2002b). The immune mecha-
nism of protection appeared to require primarily CD4+ T cells,
as CD4+ T cell depletion eliminated the protective effects of 2D2
vaccination (Haque et al., 2006a).
In another attenuated vaccine approach, a B. pseudomallei cap-
sular mutant (B. pseudomallei 1E10) was evaluated as a vaccine
candidate. Immunization with the capsular mutant 1E10 by the
i.p. route resulted in no protection against virulent challenge
(Atkins et al., 2002a).
Transposon mutants of B. pseudomallei have also been evalu-
ated as candidate vaccines. Mutants in several key Burkholderia
biosynthetic pathways (purN, purM, hisF, and pabB) have been
investigated for protective immunogenicity (Pilatz et al., 2006;
Breitbach et al., 2008). All of the mutant strains conferred some
degree of protection against virulent challenge in susceptible
BALB/c mice. Mice immunized by the intranasal and i.p. routes
with the purN mutant were protected from acute infection fol-
lowing intranasal challenge (Breitbach et al., 2008). However,
vaccinated mice were not protected from the development of
chronic infection. The immunogenicity of a purM mutant strain
of B. pseudomallei was also evaluated, but was found to provide
only partial protection from virulent challenge, and immuniza-
tion by either the intranasal or i.p. routes did not appear to affect
protective efficacy (Breitbach et al., 2008). It was speculated that
the greater apparent immunogenicity of the purN mutant bac-
terium was due to greater persistence of this strain following
vaccination than the purM strain.
It should also be noted that a purM mutant strain (Bp82) of
B. pseudomallei was recently approved by the CDC for use as an
approved BSL2 level organism (Propst et al., 2010). This attenu-
ated strain of B. pseudomalleiwas shown to be extremely safe even
in very immune compromised animals.
aroB auxotrophic mutant strain 13B11 has also been evaluated
as a candidate live attenuated vaccine (Cuccui et al., 2007). The
13B11 aroB mutant strain did not cause disease in mice when
inoculated at either 1× 105 or 1× 106 CFU by the intranasal
route. Furthermore, the aroB mutant was cleared from the lungs
and spleen of mice within 3 days. Vaccinated mice showed an
increased time to death when challenged with virulent B. pseu-
domallei but in the end all mice succumbed to the infection
(Cuccui et al., 2007). An aroC deletion mutant of B. pseudoma-
llei (A2) was also tested as a vaccine candidate (Foulongne et al.,
2001; Srilunchang et al., 2009). Immunization with A2 by the i.p.
route provided significant protection against virulent challenge in
C57Bl/6 mice, but not in BALB/c mice (Srilunchang et al., 2009).
A T3SS apparatus mutant (B. pseudomallei bipD), has also
been evaluated for protective immunity (Stevens et al., 2004;
Druar et al., 2008). Mice inoculated with the B. pseudomallei bipD
mutant strain were partially protected against subsequent chal-
lenge by the i.p. route with wild-type B. pseudomallei. In contrast,
immunization of mice with recombinant BipD protein was not
protective (Stevens et al., 2004; Druar et al., 2008).
B. mallei live attenuated vaccines
B. mallei capsule mutants and auxotrophs have been evaluated as
glanders vaccines. Mice immunized by the aerosol route with a
capsule mutant (DD3008) of B. mallei strain ATCC23344 devel-
oped high antibody responses (Ulrich et al., 2005). However,
mice were not protected against aerosol challenge with a high
dose of virulent B. mallei, presumably in part because the lack
of mucosal IgA or IgG antibody responses (Ulrich et al., 2005).
Immunization with an auxotrophic mutant of B. mallei (ILV1)
elicited a Th1-like IgG subclass (IgG2a) antibody response, and
provided significant short-term survival to challenge by the
aerosol route with virulent B. mallei. In addition, immuniza-
tion also provided significant protection to challenge by the
aerosol route. It should be noted, however, that all mice surviv-
ing acute challenge developed chronic infection. It was speculated
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that the axotrophic mutants were more effective immunogens
than capsule mutants (Amemiya, 2002; Ulrich et al., 2005). An
attenuated ctpA mutant of B. mallei was also evaluated as a
live attenuated vaccine, and found to provide partial protection
against i.p. inoculation with virulent B. mallei (Bandara et al.,
2008).
INACTIVATEDWHOLE CELL Burkholderia VACCINES
Immunization with killed whole bacteria (bacterin vaccines) has
been shown previously to provide effective immunization against
a variety of bacterial diseases. These vaccines are relatively simple
to produce and are safer than live attenuated vaccines and provide
relatively high levels of specific immunity. However, vaccine site
reactions are a potential problem with this class of vaccines.
Burkholderia pseudomallei killed vaccines
Live B. pseudomallei NCTC 13179, killed bacterial cells alone, or
culture filtrate antigens (CFA) or lysates from B. pseudomallei
cultures were tested as candidate vaccines following administra-
tion by the s.c. or i.v. routes, in BALB/c and C57BL/6 mouse
i.v. challenge models. The live vaccine as well as lysates from
B. pseudomallei and killed bacterial cells mixed with complete
Freund’s adjuvant all induced protective immunity. However,
only the live vaccine stimulated a Th1 immune response (Barnes
and Ketheesan, 2007).
In another study, the ability of vaccine adjuvants to enhance
the immunogenicity of killed Burkholderia vaccines was evalu-
ated. Mice were immunized intranasally with heat-killed B. pseu-
domallei, with or without a liposomal adjuvant (CLDC) and
protective immunity to intranasal challenge assessed (Henderson
et al., 2011). Immunization with CLDC adjuvant plus heat killed
bacteria gave superior immunity compared to immunization with
heat-killed bacteria alone.
The relative ability of heat-killed vaccines prepared with
Burkholderia thailandensis, B. mallei, or B. pseudomallei cells
was compared for induction of protection against melioidosis
and glanders (Whitlock et al., 2008; Sarkar-Tyson et al., 2009;
Henderson et al., 2011). Both the B. mallei and B. pseudomallei
vaccines provided significant protection against B. pseudomallei
challenge, whereas the B. thailandensis vaccine failed to elicit pro-
tective immunity. The probable mechanism of protection may
have involved induction of antibody responses to the CPS and LPS
and was CD4+ T cell dependent (Sarkar-Tyson et al., 2009).
Burkholderia mallei killed vaccines
Immunization with heat-killed B. mallei vaccines was evaluated
for evidence of protection in mouse challenge models. Mice
immunized i.p. with a heat-killed B. mallei vaccine were signifi-
cantly protected from i.p. challenge with B. mallei (Whitlock et al.,
2008). Antibody depletion studies indicated that both CD4+ T
cells and B cells were required for induction of effective immu-
nity following immunization with the heat killed vaccine, whereas
CD8+ T cells appeared to be dispensable. Depletion of IFN-γ
or TNF-α immediately prior to challenge also reduced vaccine
effectiveness, suggesting a role for these cytokines in protective
immunity.
Alternative vaccine approaches
Dendritic cell vectored vaccines have been shown to induce effec-
tive immunity against both pathogens and cancer. A DC vaccine
prepared using DC pulsed in vitro with heat-killed B. pseudoma-
llei was evaluated for effectiveness in a mouse B. pseudomallei
challenge model (Elvin et al., 2006). Mice receiving the DC vac-
cine were significantly protected against challenge with virulent
B. pseudomallei when delivered by the i.p. route.
Outer membrane vesicles (OMVs), which are secreted by bac-
teria during in vitro culture, have also been evaluated as candidate
immunogens for Burkholderia pseudomallei and mallei (Hara
et al., 2009; Nieves et al., 2011; Schell et al., 2011). Immunization
with B. pseudomalleiOMVs by the s.c. route was found recently to
produce significant protection against pulmonary challenge with
virulent B. pseudomallei. Induction of both cellular and humoral
responses to vaccination was observed. Interestingly, immuniza-
tion with OMVs by the intranasal route was not effective in
generating protective immunity. OMV immunization also did not
provide protection against chronic infection (Nieves et al., 2011).
The bacterial Elongation Factor-Tu (EF-Tu), which is also
secreted in OMVs is immunogenic (Harding et al., 2007), and was
evaluated as a vaccine antigen (Nieves et al., 2010). Immunization
by the intranasal route resulted in reduced bacterial burden when
mice were subjected to intranasal challenge with B. thailandensis
(Nieves et al., 2010).
CHALLENGES FACING Burkholderia VACCINE
DEVELOPMENT
While substantial progress has been made in the development
of effective vaccines for Burkholderia, significant hurdles still
remain. In the case of subunit vaccines, it is not clear whether
new and more immunogenic target antigens have yet to be dis-
covered. High throughput screening strategies may facilitate the
identification of such antigens. In addition, the development of
new polyvalent vaccines may provide more effective and broader
coverage against B. pseudomallei infection than single subunit
vaccines, which is particularly important given the high genetic
diversity of different B. pseudomallei isolates, even from the same
patients.
It will also be important to more fully define the correlates
of protective immunity to Burkholderia. For example, given that
CD4+ T cells are important in protective immunity, are certain
CD4+ T cell functional subsets (eg, Th17, Th2, or Th1 cells) more
desirable than others in generating strong and long-lasting pro-
tective humoral and cellular immune responses? It is also likely
that the role of CD8+ T cells may be more important than early
studies have suggested, particularly for prevention of the chronic
stage of infection.
Given that chronic Burkholderia infection is likely contracted
via mucosal routes of exposure to Burkholderia, development of
vaccines that generate strong mucosal immune responses and IgA
production is an important goal. This will necessitate the use of
challenge models that mimic natural route of exposure, including
oral and inhalational exposure, as well as cutaneous inocula-
tion. Newer vaccine adjuvants may be particularly effective in
development of strong humoral or cellular immune responses,
or more balanced responses, depending on what is required for
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protective immunity. The route of immunization is also an
important variable, particularly for vaccines designed to provide
protection from pulmonary or oral challenge with Burkholderia.
Is there a future for a live attenuated Burkholderia vac-
cine? At present, these vaccines are the most likely to generate
full protective immunity against a broad range of Burkholderia
strains, using relatively simple immunization protocols. Whether
these vaccines will be adopted will depend on the target pop-
ulation for the intended vaccine and the willingness of local
regulatory authorities to approve live attenuated vaccines. Full
demonstration of vaccine safety and efficacy against a variety
of different challenge strains and routes can help advance the
case for live attenuated Burkholderia vaccines. Finally, while a
number of candidate vaccines have demonstrated an ability to
protect from acute challenge with Burkholderia, it is not currently
possible to provide effective protection against the development
of chronic Burkholderia infection. Thus, greater attention to
development of effective mucosal Burkholderia vaccines that are
capable of generating sterilizing immunity is warranted in the
future.
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